UT Southwestern University Hospital - William P. Clements, Jr — Dallas, Texas

UT Southwestern University Hospital - William P. Clements, Jr is a clinical research site located in Dallas, Texas, United States 75390.

Crixeo Health Trust Score: 63/100 (FAIR). This profile has not yet been claimed by the site owner.

UT Southwestern University Hospital - William P. Clements, Jr has participated in 3 clinical trials with 2 currently active.

Therapeutic areas: HER2-positive Breast Cancer, Carcinoma, Non-Small-Cell Lung, Metastatic Castration Resistant Prostate Cancer (mCRPC).

Sponsors: Seagen, a wholly owned subsidiary of Pfizer, Pfizer.

Sponsor Feasibility Report

Trust Score: 63/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UT Southwestern University Hospital - William P. Clements, Jr?

UT Southwestern University Hospital - William P. Clements, Jr has a Crixeo Trust Score of 63/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UT Southwestern University Hospital - William P. Clements, Jr conducted?

UT Southwestern University Hospital - William P. Clements, Jr has 3 clinical trials on record, with 2 currently active. Their work covers HER2-positive Breast Cancer, Carcinoma, Non-Small-Cell Lung, Metastatic Castration Resistant Prostate Cancer (mCRPC).

Is UT Southwestern University Hospital - William P. Clements, Jr accredited by Crixeo Health?

UT Southwestern University Hospital - William P. Clements, Jr has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UT Southwestern University Hospital - William P. Clements, Jr?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.